SEC Form 4 · accession 0001652252-17-000006

BIO-RAD LABORATORIES, INC. · BIO BIO.B

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP, Chief Strategy Officer

Period of report

Mar 6, 2017

Accepted (ET)

Mar 7, 2017 · 3:52 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000012208

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Bio-Rad A Common Stock^F1	Mar 6, 2017	S	998	$196.1637	D	12,656	D
Bio-Rad A Common Stock	Mar 6, 2017	M	3,500	$75.32	A	16,156	D
Bio-Rad A Common Stock^F2	Mar 6, 2017	S	3,500	$195.8652	D	12,656	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-Qualified Stock Option (right to buy)^F3	$75.32	Mar 6, 2017	M	3,500	D	—	Aug 1, 2017	Bio-Rad A Common Stock	3,500	0	D

F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.15 to $196.25, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $195.11 to $196.40, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3The option vested in five equal annual installments beginning August 1, 2008.